Trade Cassava Sciences, Inc. - SAVA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.10 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Cassava Sciences Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 20.45 |
| Open* | 20.45 |
| 1-Year Change* | -12.79% |
| Day's Range* | 20.45 - 21.08 |
| 52 wk Range | 12.32-38.53 |
| Average Volume (10 days) | 1.00M |
| Average Volume (3 months) | 27.14M |
| Market Cap | 1.09B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 42.24M |
| Revenue | N/A |
| EPS | -2.29 |
| Dividend (Yield %) | N/A |
| Beta | -0.39 |
| Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 20.45 | 0.74 | 3.75% | 19.71 | 20.76 | 19.68 |
| Apr 19, 2024 | 19.55 | -1.27 | -6.10% | 20.82 | 21.06 | 19.34 |
| Apr 18, 2024 | 21.05 | 0.09 | 0.43% | 20.96 | 21.89 | 20.70 |
| Apr 17, 2024 | 21.20 | 0.42 | 2.02% | 20.78 | 21.51 | 20.66 |
| Apr 16, 2024 | 20.97 | 1.16 | 5.86% | 19.81 | 21.65 | 19.31 |
| Apr 15, 2024 | 19.86 | -2.02 | -9.23% | 21.88 | 22.80 | 19.51 |
| Apr 12, 2024 | 22.71 | -3.15 | -12.18% | 25.86 | 26.35 | 22.38 |
| Apr 11, 2024 | 25.93 | 1.56 | 6.40% | 24.37 | 26.61 | 24.23 |
| Apr 10, 2024 | 24.45 | 0.18 | 0.74% | 24.27 | 25.24 | 23.91 |
| Apr 9, 2024 | 25.37 | 1.63 | 6.87% | 23.74 | 25.53 | 22.93 |
| Apr 8, 2024 | 23.51 | 2.51 | 11.95% | 21.00 | 24.05 | 20.96 |
| Apr 5, 2024 | 21.25 | 1.09 | 5.41% | 20.16 | 21.36 | 20.16 |
| Apr 4, 2024 | 20.41 | 0.01 | 0.05% | 20.40 | 20.83 | 20.16 |
| Apr 3, 2024 | 20.53 | 1.02 | 5.23% | 19.51 | 20.56 | 19.36 |
| Apr 2, 2024 | 19.66 | -0.08 | -0.41% | 19.74 | 19.93 | 19.34 |
| Apr 1, 2024 | 20.24 | 0.25 | 1.25% | 19.99 | 20.83 | 19.70 |
| Mar 28, 2024 | 20.20 | 0.12 | 0.60% | 20.08 | 20.61 | 19.93 |
| Mar 27, 2024 | 20.26 | 0.77 | 3.95% | 19.49 | 20.40 | 19.47 |
| Mar 26, 2024 | 19.63 | -0.13 | -0.66% | 19.76 | 20.07 | 19.42 |
| Mar 25, 2024 | 19.55 | -0.63 | -3.12% | 20.18 | 20.69 | 19.55 |
Cassava Sciences, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, April 29, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 Cassava Sciences Inc Earnings Release Q1 2024 Cassava Sciences Inc Earnings ReleaseForecast -Previous - |
| Friday, May 3, 2024 | ||
| Time (UTC) 15:00 | Country US
| Event Cassava Sciences Inc Annual Shareholders Meeting Cassava Sciences Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, May 9, 2024 | ||
| Time (UTC) 15:00 | Country US
| Event Cassava Sciences Inc Annual Shareholders Meeting Cassava Sciences Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, August 1, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 Cassava Sciences Inc Earnings Release Q2 2024 Cassava Sciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 80.02 | 32.868 | 6.446 | 4.959 | 6.662 |
| Selling/General/Admin. Expenses, Total | 11.988 | 8.055 | 3.739 | 3.391 | 3.693 |
| Research & Development | 7.262 | 5.935 | |||
| Operating Income | -80.02 | -32.868 | -6.446 | -4.959 | -6.662 |
| Interest Income (Expense), Net Non-Operating | 2.777 | 0.049 | 0.112 | 0.328 | 0.105 |
| Net Income Before Taxes | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Net Income After Taxes | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Net Income Before Extra. Items | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Net Income | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Income Available to Common Excl. Extra. Items | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Income Available to Common Incl. Extra. Items | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Diluted Net Income | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Diluted Weighted Average Shares | 40.202 | 39.405 | 26.105 | 17.412 | 10.682 |
| Diluted EPS Excluding Extraordinary Items | -1.89657 | -0.82185 | -0.24264 | -0.26597 | -0.61384 |
| Diluted Normalized EPS | -1.89657 | -0.82185 | -0.25589 | -0.26597 | -0.61384 |
| Other Operating Expenses, Total | 60.77 | 18.878 | 3.053 | 1.568 | 2.969 |
| Unusual Expense (Income) | 0 | -0.346 | |||
| Other, Net | 0.997 | 0.434 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 28.777 | 26.512 | 20.937 | 21.345 | 19.917 |
| Selling/General/Admin. Expenses, Total | 3.808 | 4.392 | 3.285 | 2.819 | 2.969 |
| Unusual Expense (Income) | |||||
| Other Operating Expenses, Total | |||||
| Operating Income | -28.777 | -26.512 | -20.937 | -21.345 | -19.917 |
| Interest Income (Expense), Net Non-Operating | 2.198 | 2.051 | 1.554 | 0.878 | 0.314 |
| Net Income Before Taxes | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Net Income After Taxes | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Net Income Before Extra. Items | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Net Income | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Income Available to Common Excl. Extra. Items | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Income Available to Common Incl. Extra. Items | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Diluted Net Income | -26.376 | -24.271 | -19.134 | -20.257 | -19.328 |
| Diluted Weighted Average Shares | 41.793 | 41.739 | 40.781 | 40.05 | 40.015 |
| Diluted EPS Excluding Extraordinary Items | -0.63111 | -0.58149 | -0.46919 | -0.50579 | -0.48302 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.63111 | -0.58149 | -0.46919 | -0.50579 | -0.48302 |
| Other, Net | 0.203 | 0.19 | 0.249 | 0.21 | 0.275 |
| Research & Development | 24.969 | 22.12 | 17.652 | 18.526 | 16.948 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 211.226 | 244.482 | 93.994 | 23.349 | 20.04 |
| Cash and Short Term Investments | 201.015 | 233.437 | 93.506 | 23.081 | 19.807 |
| Cash & Equivalents | 201.015 | 233.437 | 93.506 | 23.081 | 19.807 |
| Short Term Investments | |||||
| Other Current Assets, Total | 0.16 | 0.053 | 0.488 | 0.268 | 0.233 |
| Total Assets | 234.834 | 266.782 | 94.3 | 23.486 | 20.139 |
| Property/Plant/Equipment, Total - Net | 22.986 | 20.826 | 0.306 | 0.137 | 0.087 |
| Property/Plant/Equipment, Total - Gross | 24.186 | 21.222 | 0.889 | 0.947 | 0.987 |
| Accumulated Depreciation, Total | -1.2 | -0.396 | -0.878 | -0.9 | -0.9 |
| Other Long Term Assets, Total | 0 | 0.399 | 0 | 0.012 | |
| Total Current Liabilities | 7.063 | 12.534 | 1.865 | 1.387 | 0.511 |
| Accounts Payable | 4.017 | 7.126 | 0.911 | 0.453 | 0.294 |
| Accrued Expenses | 2.554 | 4.777 | 0.86 | 0.925 | 0.217 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 7.295 | 12.867 | 2.1 | 1.387 | 0.511 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 227.539 | 253.915 | 92.2 | 22.099 | 19.628 |
| Common Stock | 0.042 | 0.04 | 0.035 | 0.022 | 0.017 |
| Additional Paid-In Capital | 511.049 | 461.181 | 267.086 | 190.664 | 183.567 |
| Retained Earnings (Accumulated Deficit) | -283.552 | -207.306 | -174.921 | -168.587 | -163.956 |
| Total Liabilities & Shareholders’ Equity | 234.834 | 266.782 | 94.3 | 23.486 | 20.139 |
| Total Common Shares Outstanding | 41.7356 | 40.0168 | 35.238 | 21.8418 | 17.2193 |
| Other Liabilities, Total | 0.232 | 0.333 | 0.235 | 0 | 0 |
| Preferred Stock - Non Redeemable, Net | 0 | ||||
| Other Equity, Total | |||||
| Other Current Liabilities, Total | 0.492 | 0.631 | 0.094 | 0.009 | |
| Prepaid Expenses | 10.051 | 10.992 | |||
| Intangibles, Net | 0.622 | 1.075 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 150.184 | 174.533 | 194.999 | 211.226 | 183.272 |
| Cash and Short Term Investments | 142.35 | 168.438 | 187.467 | 201.015 | 174.662 |
| Cash & Equivalents | 142.35 | 168.438 | 187.467 | 201.015 | 174.662 |
| Other Current Assets, Total | 0.189 | 0.235 | 0.277 | 0.16 | 0.079 |
| Total Assets | 172.529 | 197.248 | 218.111 | 234.834 | 207.286 |
| Property/Plant/Equipment, Total - Net | 22.077 | 22.328 | 22.609 | 22.986 | 23.274 |
| Total Current Liabilities | 17.414 | 17.895 | 13.909 | 7.063 | 8.308 |
| Accounts Payable | 9.492 | 10.338 | 8.242 | 4.017 | 3.534 |
| Accrued Expenses | 7.531 | 7.264 | 5.488 | 2.554 | 4.358 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.391 | 0.293 | 0.179 | 0.492 | 0.416 |
| Total Liabilities | 17.414 | 17.895 | 14.106 | 7.295 | 8.567 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0 | 0 | 0.197 | 0.232 | 0.259 |
| Total Equity | 155.115 | 179.353 | 204.005 | 227.539 | 198.719 |
| Common Stock | 0.042 | 0.042 | 0.042 | 0.042 | 0.04 |
| Additional Paid-In Capital | 514.923 | 513.51 | 511.786 | 511.049 | 463.097 |
| Retained Earnings (Accumulated Deficit) | -359.85 | -334.199 | -307.823 | -283.552 | -264.418 |
| Total Liabilities & Shareholders’ Equity | 172.529 | 197.248 | 218.111 | 234.834 | 207.286 |
| Total Common Shares Outstanding | 42.1298 | 41.9195 | 41.7494 | 41.7356 | 40.0595 |
| Prepaid Expenses | 6.36 | 4.532 | 7.255 | 10.051 | 8.531 |
| Other Long Term Assets, Total | 0 | 0 | |||
| Intangibles, Net | 0.268 | 0.387 | 0.503 | 0.622 | 0.74 |
| Property/Plant/Equipment, Total - Gross | 24.094 | 24.072 | 24.081 | 24.186 | 24.203 |
| Accumulated Depreciation, Total | -2.017 | -1.744 | -1.472 | -1.2 | -0.929 |
| Total Receivables, Net | 1.285 | 1.328 | |||
| Accounts Receivable - Trade, Net | 1.285 | 1.328 | |||
| Preferred Stock - Non Redeemable, Net | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.246 | -32.385 | -6.334 | -4.631 | -6.557 |
| Cash From Operating Activities | -77.514 | -30.196 | -5.382 | -2.514 | -4.77 |
| Cash From Operating Activities | 0.804 | 0.31 | 0.022 | 0.058 | 0.069 |
| Non-Cash Items | 2.066 | 1.759 | 0.642 | 1.296 | 2.388 |
| Changes in Working Capital | -4.635 | -0.104 | 0.288 | 0.763 | -0.67 |
| Cash From Investing Activities | -2.712 | -22.214 | 0.36 | -0.018 | 0 |
| Capital Expenditures | -2.712 | -22.214 | -0.018 | ||
| Other Investing Cash Flow Items, Total | 0 | 0 | 0.36 | 0 | |
| Cash From Financing Activities | 47.804 | 192.341 | 75.447 | 5.806 | 14.098 |
| Financing Cash Flow Items | -0.06 | ||||
| Issuance (Retirement) of Stock, Net | 47.804 | 192.341 | 75.447 | 5.866 | 14.098 |
| Net Change in Cash | -32.422 | 139.931 | 70.425 | 3.274 | 9.328 |
| Amortization | 0.497 | 0.224 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.271 | -76.246 | -57.112 | -36.855 | -17.527 |
| Cash From Operating Activities | -13.255 | -77.514 | -56.194 | -34.644 | -23.53 |
| Cash From Operating Activities | 0.272 | 0.804 | 0.533 | 0.352 | 0.178 |
| Non-Cash Items | 0.673 | 2.066 | 1.45 | 0.98 | 0.495 |
| Changes in Working Capital | 9.952 | -4.635 | -1.444 | 0.619 | -6.811 |
| Cash From Investing Activities | -0.357 | -2.712 | -3.047 | -1.891 | -0.425 |
| Other Investing Cash Flow Items, Total | 0 | ||||
| Cash From Financing Activities | 0.064 | 47.804 | 0.466 | 0.33 | 0.211 |
| Issuance (Retirement) of Stock, Net | 0.064 | 47.804 | 0.466 | 0.33 | 0.211 |
| Net Change in Cash | -13.548 | -32.422 | -58.775 | -36.205 | -23.744 |
| Capital Expenditures | -0.357 | -2.712 | -3.047 | -1.891 | -0.425 |
| Amortization | 0.119 | 0.497 | 0.379 | 0.26 | 0.135 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cassava Sciences Inc. Company profile
Cassava Science Inc is a clinical-stage biopharmaceutical company that specialises in detecting and treating Alzheimer’s disease, an incurable progressive neurologic disorder, which is . The company is listed on the Nasdaq under the ticker SAVA.
According to Cassava, over five million people in the US have Alzheimer’s. The company focuses on research and development to find new approaches for its treatment and diagnosis.
Cassava is developing Simufilam for the proposed treatment of Alzheimer's. According to the company, Simufilam is a proprietary oral drug candidate, developed in-house with academic collaborators. Simufilam, or PTI-125, is the company’s lead therapeutic product candidate. It’s currently (17 March) undergoing Phase 3 clinical studies.
SavaDx is the company’s investigational diagnostic for Alzheimer’s. According to the company, SavaDx is being developed to detect the disease with a simple blood test. However, SavaDx is still an early-stage product candidate and a lower priority than Simufilam, Cassava said.
Cassava was incorporated in 1998. It’s based in Austin, Texas, US. Remi Barbier has served as president, CEO and chairman of the board of directors since the company’s inception. Nadav Friedmann is the company’s chief medical officer. James Kupiec is the chief clinical development officer.
| Industry: | Bio Therapeutic Drugs |
6801 N Capital Of Texas Highway
Building 1; Suite 300
AUSTIN
TEXAS 78731
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com